xploration of the Expression and Preliminary Mechanisms of Estrogen and Progesterone Responsive Molecules in Progesterone Resistance

Data Description: Molecular Profiling of Progesterone Resistance in Atypical Endometrial Hyperplasia

Research Objective & Hypothesis
This study investigates the molecular basis of progesterone resistance in atypical endometrial hyperplasia (AEH). We hypothesized that resistance arises from synergistic dysregulation across three pathways: estrogen signaling overactivation, progesterone signaling impairment, and sustained cellular proliferation.

Data Collection Methods

· Source: Endometrial tissues from 20 AEH patients after 6-month progestin therapy, stratified into progesterone-resistant (n=10) and sensitive (n=10) groups.
· Immunohistochemistry (IHC): Quantified protein expression and localization via specific antibodies and ImageJ analysis (Mean Optical Density).
· Western Blot (WB): Validated protein levels through SDS-PAGE and densitometric quantification.
· Statistical Analysis: Unpaired t-tests (GraphPad Prism 9); significance at p < 0.05.

Key Findings & Data Interpretation

1. IHC Data

· What it shows: Visual and quantitative protein expression in tissue context.
· Estrogen Axis: Significant upregulation of ERα, pS2, and MUC1 in resistant tissues, indicating sustained estrogenic activity.
· Progesterone Axis: Coordinated downregulation of PR, its co-chaperones (FKBP4, FKBP5), and downstream effector FOSL2, demonstrating comprehensive progesterone signaling failure.
· Proliferation Markers : Elevated SOX7 and Ki-67 in resistant group, confirming persistent proliferation despite treatment.

2. Western Blot Data
· What it shows: Biochemical validation of protein expression trends.
· Figure 3A-C: Confirmed significant downregulation of progesterone pathway components (FKBP4, FKBP5, FOSL2).
· Figure 3C-D: Validated upregulation of SOX7 and estrogen-responsive effectors (pS2, MUC1).

Notable Discoveries

· Multi-pathway Dysregulation: Progesterone resistance involves synergistic failure across estrogen, progesterone, and proliferative pathways.
· Novel SOX7 Involvement: First identification of SOX7 upregulation in AEH progesterone resistance, suggesting its role in sustaining proliferation.
· Methodological Consistency: Concordant results from IHC (tissue context) and WB (biochemical validation) strengthen findings.

Data Usage Guidance
This dataset provides:

· A molecular signature for identifying progesterone-resistant AEH
· Validated targets for combination therapies (e.g., ERα or SOX7 inhibitors)
· Foundation for functional studies to establish causality